{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (sac-TMT, MK-2870) as a Monotherapy and in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less than 10 (TroFuse 11)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-open-label-study-comparing-efficacy-and-safety-of-sacituzumab-tirumotecan-sac-tmt-mk-2870-as-a-monotherapy-and-in-combination-with-pembrolizumab-mk-3475-versus-treatment-of\/#breadcrumbitem"}]}